<?xml version="1.0" encoding="UTF-8"?>
<ref id="B12-vaccines-08-00115">
 <label>12.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Negrete</surname>
    <given-names>O.A.</given-names>
   </name>
   <name>
    <surname>Wolf</surname>
    <given-names>M.C.</given-names>
   </name>
   <name>
    <surname>Aguilar</surname>
    <given-names>H.C.</given-names>
   </name>
   <name>
    <surname>Enterlein</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Muhlberger</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Su</surname>
    <given-names>S.V.</given-names>
   </name>
   <name>
    <surname>Bertolotti-Ciarlet</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Flick</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus</article-title>
  <source>PLoS Pathog.</source>
  <year>2006</year>
  <volume>2</volume>
  <elocation-id>e7</elocation-id>
  <pub-id pub-id-type="doi">10.1371/journal.ppat.0020007</pub-id>
  <?supplied-pmid 16477309?>
  <pub-id pub-id-type="pmid">16477309</pub-id>
 </element-citation>
</ref>
